Free Trial
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

Nautilus Biotechnology logo
$0.69 -0.02 (-2.21%)
Closing price 04:00 PM Eastern
Extended Trading
$0.69 0.00 (0.00%)
As of 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Key Stats

Today's Range
$0.67
$0.71
50-Day Range
$0.67
$0.82
52-Week Range
$0.66
$3.09
Volume
248,448 shs
Average Volume
205,072 shs
Market Capitalization
$86.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.13
Consensus Rating
Sell

Company Overview

Nautilus Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

NAUT MarketRank™: 

Nautilus Biotechnology scored higher than 53% of companies evaluated by MarketBeat, and ranked 526th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nautilus Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Nautilus Biotechnology has received no research coverage in the past 90 days.

  • Read more about Nautilus Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.57) to ($0.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nautilus Biotechnology is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nautilus Biotechnology is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nautilus Biotechnology has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Nautilus Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    0.46% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nautilus Biotechnology has recently increased by 11.15%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nautilus Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Nautilus Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.46% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nautilus Biotechnology has recently increased by 11.15%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Nautilus Biotechnology has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Nautilus Biotechnology this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for NAUT on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nautilus Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,550.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    41.10% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nautilus Biotechnology's insider trading history.
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NAUT Stock News Headlines

Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
See More Headlines

NAUT Stock Analysis - Frequently Asked Questions

Nautilus Biotechnology's stock was trading at $1.68 at the beginning of the year. Since then, NAUT stock has decreased by 59.1% and is now trading at $0.6870.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) posted its quarterly earnings data on Thursday, July, 31st. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02.
Read the conference call transcript
.

Top institutional shareholders of Nautilus Biotechnology include Clarius Group LLC (0.84%), Geode Capital Management LLC (0.44%), Corient Private Wealth LLC (0.34%) and Jane Street Group LLC (0.23%). Insiders that own company stock include Parag Mallick, Sujal M Patel, Subramanian Sankar, Anna Mowry, Gwen E Weld and Mary E Godwin.
View institutional ownership trends
.

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V).

Company Calendar

Last Earnings
7/31/2025
Today
8/28/2025
Next Earnings (Estimated)
10/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:NAUT
CIK
1808805
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

High Price Target
$2.50
Low Price Target
$1.75
Potential Upside/Downside
+209.3%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$70.78 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-32.53%
Return on Assets
-27.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
18.52
Quick Ratio
18.52

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.43 per share
Price / Book
0.48

Miscellaneous

Outstanding Shares
126,310,000
Free Float
74,394,000
Market Cap
$86.77 million
Optionable
Optionable
Beta
1.42
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:NAUT) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners